(Total Views: 832)
Posted On: 02/14/2022 2:22:59 PM
Post# of 36563
Excellagen: The Companies
Excellagen https://www.excellagen.com/about
Olaregen Therapeutix https://www.olaregen.com/
https://opengovny.com/corporation/5431130
https://www.sec.gov/Archives/edgar/data/17520...ry_doc.xml
https://www.floridacompanysearch.com/company?...8000073939
Generex https://generex.com/nugenerex-family-companies/#regen
The Deal
Gene Biotherapeutics https://www.otcmarkets.com/stock/CRXM/quote
https://genebiotherapeutics.com/press/
https://s3.amazonaws.com/b2icontent.irpass.cc...l93048.pdf
“Gene Biotherapeutics Announces Sale Of Excellagen Technology Platform; Retains Commercialization Rights For Greater China And Russian Federation”
The Royalties
Gene Biotherapeutics https://www.otcmarkets.com/stock/CRXM/quote
https://www.sec.gov/cgi-bin/browse-edgar?acti...arch_text=
Last 10-K https://www.sec.gov/Archives/edgar/data/77232...k.htm#a_04
“In July 2018, we sold our FDA-cleared Excellagen® product to Olaregen Therapeutix, Inc. (“Olaregen”) for aggregate consideration of up to $4,000,000. At closing, we received a cash payment of $650,000, the remaining to be paid as royalty payments of 10% of all worldwide sales of Excellagen totaling up to an additional $3,350,000. As of the date of this report, no royalties have been received. We retained rights to manufacture, market and sell Excellagen in Greater China, The Russian Federation, and the Commonwealth of Independent States (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, and Uzbekistan).”
Last 10-Q https://www.sec.gov/Archives/edgar/data/77232...rm10-q.htm
"On April 10, 2020, we transferred our residual rights in Excellagen to Shanxi Taxus Pharmaceuticals Co. Ltd."
“The Company anticipates that negative cash flows from operations will continue for the foreseeable future.”
“We intend to pursue sources of working capital from non-dilutive funding channels to support the Company’s operations that could include, but not be limited to, (1) up to $3.350 million from potential royalties from commercial sales of Excellagen® from certain geographic regions, including the United States;…”
The Promise
https://generex.com/generex-biotechnology-sub...-malaysia/
“…Olaregen Therapeutix today announced that the company has executed a Distribution Agreement with Nexgen Medical Sdn Bhd, Inc. (“Nexgen”) to be Generex’s exclusive distributor to import, market and sell the Excellagen line of wound care products in Malaysia. Nexgen is coordinating the approval of Excellagen with the Malaysian Ministry of Health and expects commercial approval by the end of May 2021.”
Nexgen Medical Sdn Bhd, Inc. http://nexgen-medical.com/
I saw no mention of Excellagen on their website.
U.S. Department of Veterans Affairs
https://www.yahoo.com/now/generex-biotechnolo...10490.html
Pharmacy Benefits Management Services https://www.pbm.va.gov/nationalformulary.asp
https://view.officeapps.live.com/op/view.aspx...BROWSELINK
I found no reference to Excellagen or Olaregen Therapeutix in my search
Conclusion
It looks to me that Excellagen is a dead end as a source of income for GNBT/NGIO
Excellagen https://www.excellagen.com/about
Olaregen Therapeutix https://www.olaregen.com/
https://opengovny.com/corporation/5431130
https://www.sec.gov/Archives/edgar/data/17520...ry_doc.xml
https://www.floridacompanysearch.com/company?...8000073939
Generex https://generex.com/nugenerex-family-companies/#regen
The Deal
Gene Biotherapeutics https://www.otcmarkets.com/stock/CRXM/quote
https://genebiotherapeutics.com/press/
https://s3.amazonaws.com/b2icontent.irpass.cc...l93048.pdf
“Gene Biotherapeutics Announces Sale Of Excellagen Technology Platform; Retains Commercialization Rights For Greater China And Russian Federation”
The Royalties
Gene Biotherapeutics https://www.otcmarkets.com/stock/CRXM/quote
https://www.sec.gov/cgi-bin/browse-edgar?acti...arch_text=
Last 10-K https://www.sec.gov/Archives/edgar/data/77232...k.htm#a_04
“In July 2018, we sold our FDA-cleared Excellagen® product to Olaregen Therapeutix, Inc. (“Olaregen”) for aggregate consideration of up to $4,000,000. At closing, we received a cash payment of $650,000, the remaining to be paid as royalty payments of 10% of all worldwide sales of Excellagen totaling up to an additional $3,350,000. As of the date of this report, no royalties have been received. We retained rights to manufacture, market and sell Excellagen in Greater China, The Russian Federation, and the Commonwealth of Independent States (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, and Uzbekistan).”
Last 10-Q https://www.sec.gov/Archives/edgar/data/77232...rm10-q.htm
"On April 10, 2020, we transferred our residual rights in Excellagen to Shanxi Taxus Pharmaceuticals Co. Ltd."
“The Company anticipates that negative cash flows from operations will continue for the foreseeable future.”
“We intend to pursue sources of working capital from non-dilutive funding channels to support the Company’s operations that could include, but not be limited to, (1) up to $3.350 million from potential royalties from commercial sales of Excellagen® from certain geographic regions, including the United States;…”
The Promise
https://generex.com/generex-biotechnology-sub...-malaysia/
“…Olaregen Therapeutix today announced that the company has executed a Distribution Agreement with Nexgen Medical Sdn Bhd, Inc. (“Nexgen”) to be Generex’s exclusive distributor to import, market and sell the Excellagen line of wound care products in Malaysia. Nexgen is coordinating the approval of Excellagen with the Malaysian Ministry of Health and expects commercial approval by the end of May 2021.”
Nexgen Medical Sdn Bhd, Inc. http://nexgen-medical.com/
I saw no mention of Excellagen on their website.
U.S. Department of Veterans Affairs
https://www.yahoo.com/now/generex-biotechnolo...10490.html
Pharmacy Benefits Management Services https://www.pbm.va.gov/nationalformulary.asp
https://view.officeapps.live.com/op/view.aspx...BROWSELINK
I found no reference to Excellagen or Olaregen Therapeutix in my search
Conclusion
It looks to me that Excellagen is a dead end as a source of income for GNBT/NGIO
(1)
(0)
